Cargando…

Therapeutic enzyme engineering using a generative neural network

Enhancing the potency of mRNA therapeutics is an important objective for treating rare diseases, since it may enable lower and less-frequent dosing. Enzyme engineering can increase potency of mRNA therapeutics by improving the expression, half-life, and catalytic efficiency of the mRNA-encoded enzym...

Descripción completa

Detalles Bibliográficos
Autores principales: Giessel, Andrew, Dousis, Athanasios, Ravichandran, Kanchana, Smith, Kevin, Sur, Sreyoshi, McFadyen, Iain, Zheng, Wei, Licht, Stuart
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8795449/
https://www.ncbi.nlm.nih.gov/pubmed/35087131
http://dx.doi.org/10.1038/s41598-022-05195-x
_version_ 1784641074046697472
author Giessel, Andrew
Dousis, Athanasios
Ravichandran, Kanchana
Smith, Kevin
Sur, Sreyoshi
McFadyen, Iain
Zheng, Wei
Licht, Stuart
author_facet Giessel, Andrew
Dousis, Athanasios
Ravichandran, Kanchana
Smith, Kevin
Sur, Sreyoshi
McFadyen, Iain
Zheng, Wei
Licht, Stuart
author_sort Giessel, Andrew
collection PubMed
description Enhancing the potency of mRNA therapeutics is an important objective for treating rare diseases, since it may enable lower and less-frequent dosing. Enzyme engineering can increase potency of mRNA therapeutics by improving the expression, half-life, and catalytic efficiency of the mRNA-encoded enzymes. However, sequence space is incomprehensibly vast, and methods to map sequence to function (computationally or experimentally) are inaccurate or time-/labor-intensive. Here, we present a novel, broadly applicable engineering method that combines deep latent variable modelling of sequence co-evolution with automated protein library design and construction to rapidly identify metabolic enzyme variants that are both more thermally stable and more catalytically active. We apply this approach to improve the potency of ornithine transcarbamylase (OTC), a urea cycle enzyme for which loss of catalytic activity causes a rare but serious metabolic disease.
format Online
Article
Text
id pubmed-8795449
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-87954492022-01-28 Therapeutic enzyme engineering using a generative neural network Giessel, Andrew Dousis, Athanasios Ravichandran, Kanchana Smith, Kevin Sur, Sreyoshi McFadyen, Iain Zheng, Wei Licht, Stuart Sci Rep Article Enhancing the potency of mRNA therapeutics is an important objective for treating rare diseases, since it may enable lower and less-frequent dosing. Enzyme engineering can increase potency of mRNA therapeutics by improving the expression, half-life, and catalytic efficiency of the mRNA-encoded enzymes. However, sequence space is incomprehensibly vast, and methods to map sequence to function (computationally or experimentally) are inaccurate or time-/labor-intensive. Here, we present a novel, broadly applicable engineering method that combines deep latent variable modelling of sequence co-evolution with automated protein library design and construction to rapidly identify metabolic enzyme variants that are both more thermally stable and more catalytically active. We apply this approach to improve the potency of ornithine transcarbamylase (OTC), a urea cycle enzyme for which loss of catalytic activity causes a rare but serious metabolic disease. Nature Publishing Group UK 2022-01-27 /pmc/articles/PMC8795449/ /pubmed/35087131 http://dx.doi.org/10.1038/s41598-022-05195-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Giessel, Andrew
Dousis, Athanasios
Ravichandran, Kanchana
Smith, Kevin
Sur, Sreyoshi
McFadyen, Iain
Zheng, Wei
Licht, Stuart
Therapeutic enzyme engineering using a generative neural network
title Therapeutic enzyme engineering using a generative neural network
title_full Therapeutic enzyme engineering using a generative neural network
title_fullStr Therapeutic enzyme engineering using a generative neural network
title_full_unstemmed Therapeutic enzyme engineering using a generative neural network
title_short Therapeutic enzyme engineering using a generative neural network
title_sort therapeutic enzyme engineering using a generative neural network
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8795449/
https://www.ncbi.nlm.nih.gov/pubmed/35087131
http://dx.doi.org/10.1038/s41598-022-05195-x
work_keys_str_mv AT giesselandrew therapeuticenzymeengineeringusingagenerativeneuralnetwork
AT dousisathanasios therapeuticenzymeengineeringusingagenerativeneuralnetwork
AT ravichandrankanchana therapeuticenzymeengineeringusingagenerativeneuralnetwork
AT smithkevin therapeuticenzymeengineeringusingagenerativeneuralnetwork
AT sursreyoshi therapeuticenzymeengineeringusingagenerativeneuralnetwork
AT mcfadyeniain therapeuticenzymeengineeringusingagenerativeneuralnetwork
AT zhengwei therapeuticenzymeengineeringusingagenerativeneuralnetwork
AT lichtstuart therapeuticenzymeengineeringusingagenerativeneuralnetwork